<?xml version="1.0" encoding="UTF-8"?>
<p id="p0200">In Part II of our 2-part series on the COVID-19 pandemic, and the corresponding global human crisis in has produced, we advance the innovative hypothesis that the repurposed application of high-dose methotrexate with leucovorin rescue, represents a particularly interesting candidate therapy, worthy of investigation within the context of a randomized, controlled clinical trial, in order to confirm or refute the contention that this WHO designated essential treatment can uncouple the SARS-CoV-2 triggered constellation of immune activities that compositionally represent the highly injurious PANIC Attack which leads to obliteration of the bronchopulmonary alveolar gas-exchange apparatus, predisposing the severe COVID-19 patient to disabling morbidity, and a significant risk of mortality.</p>
